Seeking Alpha

TFF Pharmaceuticals Awarded $2.97 Million to Develop Universal Influenza Vaccine

FORT WORTH, Texas, June 26, 2023 (GLOBE NEWSWIRE) -- TFF Pharmaceuticals, Inc. (TFFP) (“the Company”), a clinical-stage biopharmaceutical company focused on developing and commercializing innovative ...
Seeking Alpha

TFF Pharmaceuticals to Participate in the 2023 Jefferies Healthcare Conference

Please contact your Jefferies representative to schedule one-on-one meetings with the management team during the conference. A replay of the corporate presentation will be available for 90 days on the ...
FOX8 Cleveland

TFF Pharmaceuticals to Present Data from Phase 2 Trial of Voriconazole Inhalation Powder (TFF VORI) for the Treatment of Invasive Pulmonary Aspergillosis at the 11th Advances ...

TFF Pharmaceuticals’ proprietary Thin Film Freezing (TFF) technology allows for the transformation of both existing compounds and new chemical entities into dry powder formulations exhibiting unique ...
FOX40 News

TFF Pharmaceuticals Announces Acceptance of Late-Breaking Abstract for Presentation at the 44th Annual International Society for Heart and Lung Transplantation (ISHLT) 2024 Meeting

FORT WORTH, Texas, Jan. 09, 2024 (GLOBE NEWSWIRE) -- TFF Pharmaceuticals, Inc. (NASDAQ: TFFP), a clinical-stage biopharmaceutical company focused on developing and commercializing innovative drug ...
KTLA

TFF Pharmaceuticals Congratulates our Scientific Advisory Board Member, Drew Weissman, M.D., Ph.D., for Receiving the Nobel Prize in Physiology or Medicine for his Pioneering ...

FORT WORTH, Texas, Oct. 02, 2023 (GLOBE NEWSWIRE) -- TFF Pharmaceuticals, Inc. (NASDAQ: TFFP), a clinical-stage biopharmaceutical company focused on developing and commercializing innovative drug ...
FOX8 Cleveland

TFF Pharmaceuticals Reports Third Quarter 2022 Financial Results and Provides Business Update

FORT WORTH, Texas, Nov. 14, 2022 (GLOBE NEWSWIRE) -- TFF Pharmaceuticals, Inc. (NASDAQ: TFFP), a clinical-stage biopharmaceutical company focused on developing and commercializing innovative drug ...
Business Wire

TFF Pharmaceuticals Announces $25.9 Million in Financing to Further Advance Its Thin Film Freezing Technology Platform

AUSTIN, Texas--(BUSINESS WIRE)--TFF Pharmaceuticals, Inc. (NASDAQ: TFFP), a clinical-stage biopharmaceutical company focused on developing and commercializing innovative drug products based on its ...
WTNH

TFF Pharmaceuticals Makes Available Phase 2 Data from Tacrolimus Inhalation Powder (TFF TAC) for the Prevention of Lung Transplant Rejection Presented at the Recent ISHLT ...

Data Demonstrate that Treatment with TFF TAC Prevents Lung Transplant Rejection at Only One-sixth of the Dose of Oral Tacrolimus and at Two-thirds of the Oral Tacrolimus Systemic Trough Exposures Gene ...
WRIC

TFF Pharmaceuticals Announces Updated Data from the Tacrolimus Inhalation Powder (TFF TAC) and Voriconazole Inhalation Powder (TFF VORI) Clinical Programs

Eight of Eight Patients Successfully Transitioned from Oral Tacrolimus to TFF TAC with No Sign of Acute Rejection at Reduced Systemic Exposures Data from TFF VORI Phase 2 and EAP Program Continue to ...
Oklahoma's News

TFF Pharmaceuticals Announces Publication of Data Demonstrating Feasibility of Intranasal Delivery of Monoclonal Antibodies with Thin Film Freezing

FORT WORTH, Texas, Nov. 08, 2023 (GLOBE NEWSWIRE) -- TFF Pharmaceuticals, Inc. (NASDAQ: TFFP) (“the Company”), a clinical-stage biopharmaceutical company focused on developing and commercializing ...
Reuters

TFF Pharmaceuticals Announces Phase 1 Clinical Trial Progress For Voriconazole Inhalation Powder To Treat Invasive Pulmonary Aspergillosis

* TFF PHARMACEUTICALS ANNOUNCES PHASE 1 CLINICAL TRIAL PROGRESS FOR VORICONAZOLE INHALATION POWDER TO TREAT INVASIVE PULMONARY ASPERGILLOSIS Source text for Eikon: Further company coverage: ...